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Abstract
Introduction: Recent evidence suggests that intervertebral disc (IVD) cells derived from degenerative tissue are
unable to respond to physiologically relevant mechanical stimuli in the ‘normal’ anabolic manner, but instead
respond by increasing matrix catabolism. Understanding the nature of the biological processes which allow disc
cells to sense and respond to mechanical stimuli (a process termed ‘mechanotransduction’) is important to
ascertain whether these signalling pathways differ with disease. The aim here was to investigate the involvement
of interleukin (IL)-1 and IL-4 in the response of annulus fibrosus (AF) cells derived from nondegenerative and
degenerative tissue to cyclic tensile strain to determine whether cytokine involvement differed with IVD
degeneration.
Methods: AF cells were isolated from nondegenerative and degenerative human IVDs, expanded in monolayers
and cyclically strained in the presence or absence of the cytokine inhibitors IL-1 receptor antagonist (IL-1Ra) or IL-4
receptor antibody (IL-4RAb) with 10% strain at 1.0 Hz for 20 minutes using a Flexcell strain device. Total RNA was
extracted from the cells at time points of baseline control and 1 or 24 hours poststimulation. Quantitative real-time
polymerase chain reaction was used to analyse the gene expression of matrix proteins (aggrecan and type I
collagen) and enzymes (matrix metalloproteinase 3 (MMP3) and a disintegrin and metalloproteinase with a
thrombospondin type 1 motif 4 (ADAMTS4)).
Results: Expression of catabolic genes (MMP3 and ADAMTS4) decreased in AF cells derived from nondegenerative
tissue in response to 1.0-Hz stimulation, and this decrease in gene expression was inhibited or increased following
pretreatment of cells with IL-1Ra or IL-4RAb respectively. Treatment of AF cells derived from degenerative tissue
with an identical stimulus (1.0-Hz) resulted in reduced anabolic gene expression (aggrecan and type I collagen),
with IL-1Ra or IL-4RAb pretreatment having no effect.
Conclusions: Both IL-1 and IL-4 are involved in the response of AF cells derived from nondegenerative tissue to
1.0-Hz cyclic tensile strain. Interestingly, the altered response observed at 1.0-Hz in AF cells from degenerative
tissue appears to be independent of either cytokine, suggesting an alternative mechanotransduction pathway in
operation.
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Introduction
The intervertebral disc (IVD), comprising a central gela-
tinous nucleus pulposus (NP) and the peripheral col-
lagenous annulus fibrosus (AF), is a fibrocartilage pad
which functions to provide stability to the spine while
enabling flexibility through all planes. In vivo the disc is
exposed to a range of dynamic mechanical stimuli with
physiological ranges of force known to lead to matrix
homeostasis in healthy disc cells [1-7], while nonphysio-
logical magnitudes, frequencies and durations of force
result in matrix catabolism [5,8-16]. Degenerative disc
disease (DDD), characterised by the deterioration and
degradation of disc matrix, has been shown to affect
disc cell mechanobiology, leading to the inability of disc
cells to respond to physiological loads in the normal
anabolic manner. For example, Le Maitre et al. [17]
found that human NP cells derived from degenerative
IVD tissue (unlike human NP cells derived from nonde-
generative tissue) were unable to respond to hydrostatic
pressures (HP). Furthermore, we have recently shown
that the reduced catabolic response of human AF cells
derived from nondegenerative tissue exposed to 1.0-Hz
cyclic tensile strain (CTS) is aberrant in degenerative
human AF cells, resulting in an overall catabolic
response [18]. Importantly, this shift from an overall
anabolic to a predominantly catabolic response could
lead to further degradation of the extracellular matrix
(ECM) and ultimately to the progression of DDD.
Cellular mechanotransduction is defined as the process
by which a cell is able to sense a mechanical or physical
force, convert it into an intracellular biochemical signal
and thus alter cellular metabolism to regulate ECM
homeostasis. A variety of intracellular signalling proteins
and kinases have been implicated in the mechanotrans-
duction pathways of numerous cell types. These include
activation of stretch-activated and calcium-sensitive ion
channels [19], protein tyrosine phosphorylation [20], acti-
vation of protein kinase C (PKC) [21] and initiation of
mitogen-activated protein kinase (MAPK) pathways [22].
Activation of these pathways can, in turn, lead to the
synthesis of important regulatory molecules involved in
regulating tissue structure and function. These include
the synthesis of proteoglycan by IVD cells [16], the
release of nitric oxide (NO) and prostaglandins by teno-
cytes [23], the production of platelet-derived growth fac-
tor by smooth muscle cells [24], and the release of
cytokines by chondrocytes [25,26].
Although mechanical stimulation is recognised as an
important regulatory factor in IVD biology and ECM
homeostasis [27,28], studies in which IVD cell mechano-
transduction pathways have been investigated are limited.
This is surprising, as it is likely that the aberrant response
observed in disc cells derived from degenerative tissue
exposed to mechanical stimulation is due to alterations in
the mechanotransduction pathway active in these cells. It
follows, therefore, that if the mechanotransduction path-
way of disc cells derived from degenerative tissue is
altered, defining the signalling pathway could lead to the
discovery of novel therapeutic targets for the prevention
and/or treatment of DDD.
Using arginine-glycine-aspartic acid (RGD) function-
blocking peptides, Le Maitre et al. [29] showed that the
compression-induced decrease in aggrecan gene expres-
sion observed in human NP cells occurs through the
involvement of integrins in NP cells derived from non-
degenerative but not degenerative tissue, suggesting an
altered mechanotransduction pathway in operation. Liu
et al. [30] found that proteoglycan synthesis was stimu-
lated and inhibited in a heterogeneous population of
human AF and NP cells exposed to low and high HP,
respectively, with NO production levels inversely corre-
lated with proteoglycan synthesis. Furthermore, this HP-
stimulated alteration in disc cell proteoglycan synthesis
could be prevented following pretreatment of cells with
NO synthase inhibitors, suggesting NO as a mechano-
sensitive soluble mediator [30]. Similarly, using rabbit
AF cells, Rannou et al. [31] found that the 5% CTS-sti-
mulated reduction in proteoglycan synthesis occurs in
parallel with increased NO production and that, after
the addition of NO synthase inhibitors, this CTS-stimu-
lated decrease in proteoglycan synthesis was abolished.
In addition to NO, other soluble mediators, including
prostaglandins and cytokines, have also been implicated
in the mechanoresponse of cells from other tissues,
including bone cells [32-35], endothelial cells [36,37],
tendon cells [23,38] and chondrocytes [25,26,39,40].
Interestingly, a number of cytokines have been impli-
cated in mechanotransduction pathways in articular
chondrocytes, a cell type which shares many similarities
with cells of the IVD [41], although to date their invol-
vement in IVD cell mechanotransduction has not been
elucidated. Mohtai et al. [25] reported increased expres-
sion of IL-6 at the gene and protein levels in human
chondrocytes following exposure to fluid-induced shear
strains. Millward-Sadler et al. [26] found that the hyper-
polarisation response of chondrocytes derived from non-
osteoarthritic cartilage stimulated with 0.33-Hz CTS was
abolished when the cells were first treated with neutra-
lising antibodies to IL-4 and its receptors, while pre-
treatment with neutralising antibodies to IL-1 b had no
effect on this mechanoresponse. Interestingly, when the
same experiment was conducted using chondrocytes
from osteoarthritic cartilage, the electrophysiological
response to 0.33-Hz CTS was altered to a depolarisation
response and was inhibited after pretreatment with neu-
tralising antibodies to both IL-1 b and IL-4. Such data
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demonstrate the involvement of these cytokines in this
mechanoresponse, and suggests differential mechano-
transduction pathways in operation between chondro-
cytes isolated from nonosteoarthritic and osteoarthritic
cartilage [40].
IL-1 has not previously been investigated as a signal-
ling molecule in IVD cell mechanotransduction,
although it is well recognised as an important inflamma-
tory mediator in disc biology. Associated with the
pathogenesis of DDD, IL-1 stimulates catabolic gene
and protein expression and is found in greater amounts
with increasing severity of disc degeneration [42,43]. In
addition to this, IL-1 b-induced increased catabolism in
rat AF cells has been shown to be partially inhibited by
CTS treatment, suggesting a potential interaction
between these two signalling pathways [44]. Although
IL-4 has previously been described in the IVD and has
been shown to increase with degeneration, its role in
disc biology remains unknown [45,46]. However, in
chondrocyte biology, in addition to its reported role in
mechanotransduction, IL-4 functions as a chondropro-
tective cytokine capable of inhibiting the expression of
inflammatory mediators [47] and reducing catabolic
gene and protein expression [48], and has been shown
to protect against mechanically stimulated increased
matrix metalloproteinase 13 (MMP13) gene expression
in cyclically strained rat chondrocytes [49].
To date, no studies have investigated the role of these
cytokines in the mechanotransduction pathway of
mechanically stimulated IVD cells. Therefore, the aim of
this study was to investigate the involvement of IL-1
and IL-4 in human AF cell mechanotransduction and to
ascertain whether the previously observed differences in
cellular responses between AF cells derived from nonde-
generative and degenerative tissue [18] are due to an
alteration in the mechanotransduction pathways.
Materials and methods
IVD tissue
Human IVD tissue was collected from patients under-
going lumbar spinal surgery for DDD or from cadavers
(within 18 hours of death) with the consent of the
patients or their relatives and the approval of the Cen-
tral Manchester, Bury, Rochdale, Salford and Trafford
Research ethics committees. Tissue was processed for
cell extraction, and representative samples of all tissues
containing intact AF and NP regions were formalin-
fixed and paraffin-embedded, and sections were histolo-
gically graded as previously reported [41]. Graded tissue
was given a score between 0 and 12, with 0 to 3 being
classified as nondegenerative, 4 to 7 being classified as
mildly degenerative and 8 to 12 being classified as
severely degenerative. Nondegenerative IVDs were col-
lected from three cadavers (mean donor age, 47 years;
age range, 37 to 57 years), and histologically degenera-
tive IVDs were collected from two patients who had
undergone surgery for DDD and from one cadaver
(mean donor age, 50 years; age range, 29 to 66 years)
(see Table 1 for details).
Immunohistochemical analysis of cytokine receptors in
IVD cells
Paraffin-embedded AF and NP tissue obtained from a
cohort of nine individuals, including patient and post-
mortem samples (mean age, 54 years; age range, 34 to 79
years) (Table 2), were processed for immunohistochem-
ical analysis as previously reported [50,51], with articular
cartilage tissue used as a positive control. Briefly,
mounted sections were dewaxed in xylene and treated
with trypsin (Invitrogen, Paisley, UK) for antigen retrieval,
and endogenous peroxidase activity was blocked by using
hydrogen peroxide (Fisher Scientific UK Ltd, Loughbor-
ough, UK). Samples were blocked with either 10% wt/vol
rabbit serum with bovine serum albumin (BSA) (Sigma,
Poole, UK) or 10% wt/vol donkey serum with BSA
(Sigma, Poole, UK) and incubated at room temperature
for 1 hour with primary antibodies for IL-4 receptor a
(IL-4Ra) (1:300 dilution, catalogue no. MAB230; R&D
Systems, Abingdon, UK), IL-2 receptor-g (IL-2Rg) (1:10
dilution, catalogue no. MAB284; R&D Systems, Abing-
don, UK) or IL-13 receptor a1 (IL-13Ra1) (1:25 dilution,
catalogue no. AF152; R&D Systems, Abingdon, UK).
After being washed with Tris-buffered saline, samples
were incubated at room temperature for 1 hour with bio-
tinylated secondary antibodies (1:400 dilution of either
rabbit anti-mouse, catalogue no. E0464; Dako, Ely, UK; or
donkey anti-goat, catalogue no. SC-2042; Santa Cruz Bio-
technology, Santa Cruz, CA, USA), and their binding was
visualised using the streptavidin-biotin complex (Dako,
Ely, UK) technique with 3,3’-diaminobenzidine tetrahy-
drochloride solution (Sigma, Poole, UK). Sections were
counterstained with haematoxylin (Surgipath Europe Ltd,
Peterborough, UK).
Isolation and culture of AF cells
AF tissue was separated from the IVD within 24 hours
of death or surgical removal and finely minced prior to
enzymatic digestion as previously reported [18]. AF cells
were cultured in standard medium (Dulbecco’s modified
Eagle’s medium with 4.5 g/L glucose, GlutaMAX™ and
pyruvate (Gibco, Invitrogen, Paisley, UK) containing 50
μg/mL ascorbic acid, 250 ng/mL amphotericin, 100 U/
mL penicillin, 100 μg/mL streptomycin (Invitrogen) and
10% foetal calf serum (Invitrogen, Paisley, UK) and
expanded in monolayers with medium changes every 2
or 3 days. Subconfluent AF cells with passage numbers
≤6 were trypsinised (Invitrogen, Paisley, UK), seeded
onto untreated silicone membrane BioFlex culture plates
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(Flexcell International, Hillsborough, NC, USA) at a
density of 1 × 105 cells/mL in 2 mL of standard medium
and allowed to adhere for 48 hours (passage numbers >6
have been found to influence cell behaviour (J.A. Hoy-
land, unpublished data)). Media were changed to serum-
free media 15 to 17 hours prior to the application of
CTS.
Application of CTS using the Flexcell Tension™ FX-
4000™ System in the presence or absence of cytokine
inhibitors
AF cells in serum-free media adhered to Bioflex culture
plates were treated with or without the IL-1 receptor
antagonist (IL-1Ra) (0.1 μg/mL) (catalogue no. 280-RA;
R&D Systems) or a blocking antibody to the IL-4 recep-
tor (IL-4RAb) (10 μg/mL) (catalogue no. MAB230; R&D
Systems) 10 minutes prior to the application of CTS.
Using the Flexcell Tension™ FX-4000™ System, a
CTS previously shown to alter AF cell function consist-
ing of a 10% strain at 1.0-Hz frequency for 20 minutes
was delivered to the base of the silicone membranes
within the Bioflex culture plates, and consequently to
the AF cells that adhered to these membranes, using
computer-controlled negative pressure as previously
described in detail [18]. The loading regime was chosen
to be within the physiological range, with IVD tissue
strains estimated to range from 1% to 25% during com-
plex motions while compressed with a load physiologi-
cally similar to walking [52,53] and 1.0-Hz estimated to
be the frequency of locomotion [54]. Unstimulated AF
cells that adhered to Bioflex plates served as controls.
Mechanically stimulated or unstimulated cytokine inhi-
bitor-treated and untreated AF cells were incubated at
37°C with 5% CO2 for either 0 (baseline control), 1 hour
(nondegenerative AF cells) or 24 hours (degenerative AF
cells) postload, and total RNA was extracted. The time
points for mRNA analysis were chosen on the basis of
previously published observations. Of the time points
investigated (0 (baseline control), 1, 3 or 24 hours after
application of 1.0-Hz CTS), gene expression was altered
at 1 and 24 hours in AF cells derived from nondegen-
erative and degenerative IVDs, respectively [18].
Cell viability
Cell viability was assessed using the Trypan blue (0.4%;
Sigma) exclusion assay as previously reported [18].
Quantitative real-time PCR
Total RNA was extracted from each BioFlex culture
plate well using TRIzol™ reagent (Invitrogen) according
to the manufacturer’s instructions, and samples were
treated with DNase I (Ambion, Austin, TX, USA). RNA
quality and quantity were determined using the Nano-
drop ND-1000 Spectrophotometer (Nanodrop Technol-
ogies, Wilmington, DE, USA), and 500 ng of RNA were
reverse-transcribed using the High Capacity ‘cDNA’
Reverse Transcription Kit (Applied Biosystems, War-
rington, UK). A quantitative real-time polymerase chain
reaction assay was performed in triplicate using TaqMan
Universal PCR Master Mix (Applied Biosystems) with
Table 1 Intervertebral disc tissue sample details for mechanically stimulated annulus fibrosus cells
Sample Sex Mean age, yr Disc level Histological grade Source
1 Male 57 L4/L5 1 (nondegenerative) Postmortem
2 Male 46 L5/S1 1 (nondegenerative) Postmortem
3 Male 37 L5/S1 1 (nondegenerative) Postmortem
4 Male 57 L2/L3 7 (mildly degenerative) Postmortem
5 Female 29 L4/L5 9 (degenerative) Surgical (discectomy)
6 Male 66 L4/L5 9 (degenerative) Surgical (discectomy)
Table 2 Intervertebral disc tissue sample details based on immunohistochemical analysis
Sample Sex Mean age, yr Disc level Histological grade Source
1 Male 37 L4/L5 1 (nondegenerative) Postmortem
2 Male 61 L4/L5 2 (nondegenerative) Postmortem
3 Male 30 L4/L5 2 (nondegenerative) Postmortem
4 Male 61 L5/S1 5 (mildly degenerative) Postmortem
5 Male 75 L4/L5 5 (mildly degenerative) Postmortem
6 ? 34 L5/S1 5/6 (mildly degenerative) Surgical (discectomy)
7 Male 44 L4/L5 5 (mildly degenerative) Surgical (discectomy)
8 Male 59 L4/L5 7 (mildly degenerative) Postmortem
9 Male 79 L4/L5 7 (mildly degenerative) Postmortem
10 Female 28 L4/L5 9 (degenerative) Surgical (discectomy)
Gilbert et al. Arthritis Research & Therapy 2011, 13:R8
http://arthritis-research.com/content/13/1/R8
Page 4 of 12
primers and probes for glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), aggrecan and type I collagen
for degenerative AF cells, and MMP3 and a disintegrin
and metalloproteinase with a thrombospondin type 1,
motif 4 (ADAMTS4) for nondegenerative AF cells using
previously published sequences and concentrations [18].
The genes were chosen for analysis on the basis of pre-
viously published observations whereby, from among a
panel of genes investigated (aggrecan, types I and II col-
lagen, MMP3, MMP9, MMP13 and ADAMTS4), only
MMP3 and ADAMTS4 expression and aggrecan and
type I collagen gene expression were altered in 1.0-Hz
CTS-treated nondegenerative and degenerative AF cells,
respectively [18]. Data were analysed using the 2-ΔΔCT
method [18,55] and normalised to the endogenous con-
trol gene GAPDH and unloaded baseline controls.
Statistics
The nonparametric data as determined by the Shapiro-




Immunopositivity was seen for IL-4R in both AF and
NP cells from all nondegenerative and degenerative
samples and was predominantly localised intracellularly
throughout the cytoplasm and nucleus (Figures 1a and
1d). IL-2Rg immunopositivity was also seen in both AF
and NP cells from all nondegenerative and degenerative
samples, with localisation occurring intracellularly but
exclusively to the cytoplasm (Figures 1b and 1e). IL-13R
immunopositivity was seen only in the positive control
articular chondrocyte sample (Figure 1g), with no
immunopositive cells in the AF or NP tissues of the
nine samples investigated (Figures 1c and 1f).
Mechanical stimulation of cytokine inhibitor-treated AF
cells
AF cells isolated from nondegenerative and degenerative
IVDs remained viable (>90%) throughout the culture
period, with cell viability unaffected by either mechani-
cal stimulation or cytokine inhibitor treatment.
Unloaded controls showed no significant change in gene
expression for any of the genes investigated at any of
the time points analysed.
1.0-Hz CTS
Nondegenerative AF cells
There was no change in the relative gene expression of
aggrecan or type I collagen in the nondegenerative AF
cells following 1.0-Hz CTS as previously reported [18],
while MMP3 and ADAMTS4 were significantly decreased
at 1 hour post-mechanical stimulation (sixfold, P < 0.05,
and sevenfold, P < 0.05, respectively) (Figures 2a and 2b).
Treatment of AF cells from nondegenerative IVDs with
Figure 1 Immunohistochemical studies showing the localisation of interleukin (IL)-4 receptor (IL-4R), IL-common g receptor (IL-cgR)
and IL-13 receptor (IL-13R) in the human intervertebral disc. IL-4R immunopositivity in nondegenerative samples of (a) annulus fibrosus
(AF) cells and (d) nucleus pulposus (NP) cells. IL-cgR immunopositivity in nondegenerative samples of (b) AF cells and (e) NP cells. IL-13R
immunonegativity in nondegenerative samples of (c) AF cells and (f) NP cells. (g) A positive control slide is included for IL-13R in
nondegenerative articular chondrocytes. Scale bar, 25 μm.
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Figure 2 Bar graphs showing the effect of cyclic tensile strain (CTS) on matrix-degrading enzyme gene expression of annulus fibrosus
(AF) cells from nondegenerative intervertebral discs (IVDs) with or without cytokine inhibitors. Cells derived from nondegenerative IVDs
were treated with or without interleukin (IL)-1 receptor antagonist (IL-1Ra) (0.1 μg/ml) or IL-4 receptor antibody (IL-4RAb) (10 μg/ml) 10 minutes
prior to mechanical stimulation with CTS at 10% strain at 1.0 Hz for 20 minutes, then incubated for 1 hour prior to analysis. A quantitative real-
time polymerase chain reaction assay was used to analyse the gene expression of matrix-degrading enzymes (a) matrix metalloproteinase 3 and
(b) ADAMTS4 relative to the housekeeping gene GAPDH (glyceraldehyde 3-phosphate dehydrogenase) and normalised to the corresponding
unloaded baseline control. Black bars represent nondegenerative AF cells mechanically loaded without treatment, and the speckled bars and
striped bars represent cells mechanically loaded after treatment with IL-1Ra or IL-4RAb, respectively. Values are means ± SEM; n = 3. *P ≤ 0.05
denotes a significantly significant difference in gene expression between mechanically stimulated (M/S) and unstimulated baseline controls. **P
≤ 0.05) denotes a significantly significant change in gene expression between mechanically stimulated baseline controls with or without cytokine
inhibitors.
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IL-1Ra 10 minutes prior to the application of 1.0-Hz CTS
increased the baseline gene expression of MMP3 com-
pared to untreated cells (threefold, P < 0.05). However,
the application of load in the presence of IL-1Ra led to a
further increase in MMP3 gene expression 1 hour post-
CTS (twofold, P < 0.01), resulting in a significantly
altered response compared to the load-induced decrease
in MMP3 gene expression observed in untreated,
mechanically stimulated cells (P < 0.01) (Figure 2a).
IL-4RAb treatment of AF cells derived from nonde-
generative tissue had no effect on the baseline gene
expression of MMP3. However, subsequent stimulation
with CTS in the presence of IL-4RAb caused an increase
in MMP3 gene expression compared to baseline (two-
fold, P < 0.01). Thus the load-induced decrease in
MMP3 gene expression in untreated, mechanically sti-
mulated cells was altered to an increase when pretreated
with IL-4RAb (twofold, P < 0.01), with significance
achieved between pretreated and untreated mechanically
stimulated cells (P < 0.01) (Figure 2a). Incubation of
nondegenerative AF cells with IL-1Ra or IL-4RAb prior
to mechanical stimulation had no effect on the baseline
gene expression of ADAMTS4. Pretreatment with either
IL-1Ra or IL-4RAb followed by mechanical stimulation
inhibited the load-induced decrease in ADAMTS4 gene
expression compared to baseline, although this finding
did not achieve statistical significance compared to the
untreated loaded sample for both IL-1Ra- and IL-4RAb-
treated cells (Figure 2b).
Degenerative AF cells
Mechanical stimulation of AF cells derived from degen-
erative IVDs with 10% strain at 1.0-Hz frequency for 20
minutes resulted in a significant decrease in aggrecan
and type I collagen relative gene expression 24 hours
post-CTS (fivefold, P < 0.01, and sixfold, P < 0.05,
respectively) (Figures 3a and 3b). There was no change
in the relative gene expression of MMP3 or ADAMTS4
in degenerative AF cells stimulated with 1.0-Hz CTS, as
previously reported [18]. Treatment of degenerative AF
cells with IL-1Ra or IL-4RAb prior to mechanical stimu-
lation had no effect on the baseline gene expression
level of aggrecan and no effect on the CTS-induced
decrease in aggrecan gene expression, with aggrecan
gene expression remaining significantly decreased (six-
fold, P < 0.01, and fivefold, P < 0.05, for IL-1Ra-and IL-
4RAb-pretreated mechanically stimulated cells, respec-
tively) (Figure 3a). Treatment of degenerative AF cells
with IL-1Ra or IL-4RAb caused a decrease in baseline
type I collagen gene expression (threefold, P < 0.01, and
fourfold, P < 0.01, respectively). However, pretreatment
with either IL-1Ra or IL-4RAb did not inhibit the load-
induced decrease observed in type I collagen gene
expression at 24 hours post-CTS, with type I collagen
gene expression showing a further decrease compared to
pretreated, unstimulated cells (sixfold, P < 0.01, and six-
fold, P < 0.01, for IL-1Ra- and IL-4RAb-pretreated
mechanically stimulated cells, respectively) (Figure 3b).
Discussion
Mechanical stimulation in the form of CTS is important
in controlling AF cell matrix homeostasis, with the
degree of disc degeneration influencing the mechanore-
sponse of AF cells. However, to date, the molecular sig-
nalling pathways enabling AF cells to sense and respond
to mechanical stimuli, a mechanism termed ‘mechano-
transduction’, remain to be elucidated. The role of cyto-
kines as mechanotransducers has been reported in a
range of cell types, including endothelial cells [37], bone
cells [34,35], tenocytes [56-58] and chondrocytes
[25,26,40]. However, to our knowledge, this is the first
study to investigate the involvement of IL-1 and IL-4 in
IVD, specifically AF cell mechanotransduction, as well
as the first study to ascertain whether their involvement
differs with degeneration.
1.0-Hz nondegenerative tissue
When stimulated at 1.0-Hz CTS, AF cells derived from
nondegenerative tissue responded with a decrease in
MMP3 and ADAMTS4 relative gene expression, suggest-
ing a shift towards a less catabolic phenotype. This
reduced catabolic response following 1.0-Hz CTS
appears to be IL-1- and IL-4-dependent, as treatment
with the cytokine inhibitors IL-1Ra or IL-4RAb inhibited
the load-induced decrease in ADAMTS4 gene expression
and caused an increase in MMP3 gene expression.
Unexpectedly, treatment of AF cells derived from non-
degenerative tissue with IL-1Ra caused an increase in
the baseline level of MMP3 gene expression prior to
load. MMP activity has previously been shown to be
inhibited following treatment of IVD tissue with IL-1Ra
[59], suggesting that the unexpected IL-1Ra-induced
increase in MMP3 gene expression observed in this
study might correlate negatively with enzyme activity.
This potential phenomenon should be investigated
further because increased MMP gene expression in IVD
cells caused by inhibited enzyme activity due to IL-1Ra
treatment could pose a concern with regard to IL-1Ra
as a potential treatment for DDD. Although enzyme
activity may be regarded as the more biologically signifi-
cant factor, elevated levels of MMP mRNA (with the
potential for protein translation) following IL-1Ra treat-
ment could be detrimental to IVD tissue homeostasis.
Previous studies have reported modulation of
increased IL-1 b-dependent MMP gene expression fol-
lowing treatment with IL-1Ra [60]; however, the
response of MMP gene expression to IL-1Ra treatment
in the absence of IL-1 agonist has never been reported
until now. Our data indicate that, in the absence of an
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Figure 3 Bar graphs showing the effect of cyclic tensile strain (CTS) on matrix protein gene expression of annulus fibrosus (AF) cells
from degenerative intervertebral discs (IVDs) with or without cytokine inhibitors. Cells derived from degenerative IVDs were treated with
or without interleukin (IL)-1 receptor antagonist (IL-1Ra) (0.1 μg/ml) or IL-4 receptor antibody (IL-4RAb) (10 μg/ml) 10 minutes prior to
mechanical stimulation with CTS at 10% strain and 1.0 Hz for 20 minutes, then incubated for 24 hours prior to analysis. A quantitative real-time
polymerase chain reaction assay was used to analyse the gene expression of matrix proteins (a) aggrecan and (b) type I collagen relative to the
housekeeping gene GAPDH (glyceraldehyde 3-phosphate dehydrogenase) and normalised to the corresponding unloaded baseline control. Black
bars represent degenerative AF cells mechanically loaded without treatment, while speckled and striped bars represent cells mechanically loaded
after treatment with IL1-Ra or IL4-RAb, respectively. Values are means ± SEM; n = 3. *P ≤ 0.05 denotes a statistically significant change in gene
expression between mechanically stimulated (M/S) and unstimulated baseline controls.
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agonist, treatment with IL-1Ra upregulates MMP3 gene
expression by a currently undefined mechanism. It is
also worth noting that treatment with IL-4RAb had no
effect on the baseline gene expression level of MMP3 in
AF cells derived from nondegenerative tissue, suggesting
that the maintenance of baseline MMP3 gene expression
occurs independently of IL-4. Importantly, although
baseline MMP3 gene expression was upregulated follow-
ing treatment with IL-1Ra, exposure of the cells to 1.0-
Hz CTS caused a further significant increase in gene
expression. This finding is opposite to that observed in
untreated mechanically stimulated cells in which CTS
caused a decrease in MMP3 gene expression. Such
results implicate IL-1 in the CTS-induced decreased
catabolic response observed in nondegenerative AF cells.
Treatment of AF cells derived from nondegenerative
tissue with either cytokine inhibitor IL-1Ra or IL-4RAb
had no effect on the baseline gene expression level of
ADAMTS4, suggesting that the maintenance of
ADAMTS4 baseline gene expression occurs indepen-
dently of both IL-1 and IL-4. This observation is in con-
trast to IL-1Ra-dependent MMP3 baseline gene
expression. However, the CTS-induced downregulation
of ADAMTS4 gene expression in AF cells derived from
nondegenerative tissue does appear to be cytokine-
dependent, with cytokine inhibitors of both IL-1 and IL-
4 preventing the decrease in gene expression following
mechanical stimulation.
Although the expression of IL-4 has previously been
reported in the IVD [46], expression of its receptors has
not yet been described. Here we report, for the first
time, and albeit in a small number of samples, immuno-
positivity for the IL-4 receptor subunits IL-4Ra and IL-
2Rg and immunonegativity for the receptor subunit
IL-13Ra1 in human IVD cells. During IL-4R activation,
IL-4 first binds IL-4Ra, leading to the recruitment of a
second receptor subunit, predominantly IL-2Rg in cells
of haematopoietic origin [61] (termed ‘type I IL-4R’) and
IL-13Ra1 in cells of nonhaematopoietic origin [62-64]
(termed ‘type II IL-4R’). It is therefore surprising that
IL-4 appears to signal through type I IL-4R (IL-4Ra/IL-
2Rg heterodimer) in human IVD cells and not through
type II IL-4R (IL-4Ra/IL-13Ra1 heterodimer) as
reported in other cartilaginous tissues such as articular
cartilage [65]. The downstream signalling pathways acti-
vated during IL-4 signalling are IL-4R type-dependent,
with differential Janus kinase (JAK) phosphorylation
occurring between activated receptor types (phosphory-
lated JAK1/3 [66,67] and JAK2/tyrosine kinase 2 (Tyk2)
[65,68,69] following IL-4R types I and II activation,
respectively) suggesting that IL-4-dependent mechano-
transduction could differ between IVD cells and cells
from other cartilaginous tissues.
In addition to IL-4, IL-1 also appears to be necessary
for human AF cell mechanotransduction following 1.0-
Hz CTS, with similar alterations and inhibitions to the
CTS-induced decreases in MMP3 and ADAMTS4 gene
expression, respectively. IL-1 b has previously been
shown to be involved in human bone cell mechano-
transduction, where an autocrine/paracrine IL-1 b-
induced release of prostaglandin E2 is suggested to pre-
cede the 0.33-Hz CTS-induced hyperpolarisation
response [35]. IL-1 b has also been implicated in
osteoarthritic (but not nonosteoarthritic) chondrocyte
mechanotransduction, where the pretreatment of cells
with neutralising antibodies to IL-1 b prevented the
CTS-induced depolarisation response, suggesting altered
mechanotransduction in chondrocytes derived from
degenerative tissue [40]. Although in our study it is not
clear which subtype of IL-1 is involved in AF cell
mechanotransduction, information from other studies of
connective tissue mechanical loading suggests IL-1 b as
the primary candidate [35,40]. Although the involvement
of IL-1 in disc cell mechanotransduction has not pre-
viously been reported, the expression of IL-1 (IL-1a and
IL-1 b), its antagonist (IL-1Ra) and its receptor (IL-1
receptor, type I) have been reported in both nondegen-
erative and degenerative IVDs, with the IL-1 agonists,
but not the IL-1 antagonist, increasing with the severity
of degeneration [42]. Furthermore, evidence from a
study using rats suggests that potential interactions exist
between the IL-1 and CTS signalling pathways in AF
cells as demonstrated by the partial inhibition of IL-1 b-
induced catabolic gene expression with the addition of
6% CTS treatment [44]. Thus, in addition to the role of
IL-1 as a catabolic factor implicated in DDD, our find-
ings support the concept that it may play a role in
transducing physiological mechanical stimuli leading to
tissue remodelling.
1.0-Hz degenerative tissue: an altered
mechanotransduction pathway with disease
When AF cells derived from degenerative tissue were
subjected to 1.0-Hz CTS, the observed response,
reduced relative gene expression of the matrix proteins
aggrecan and type I collagen, did not appear to involve
either IL-1 or IL-4 as demonstrated by the inability of
the cytokine inhibitors IL-1Ra and IL-4RAb to prevent
the CTS-induced changes in gene expression. Although
pretreatment with either cytokine inhibitor had no effect
on the baseline gene expression level of aggrecan in AF
cells derived from degenerative tissue, type I collagen
baseline gene expression was reduced in these cells.
This reduced type I collagen baseline gene expression
might be expected following IL-4Rab treatment, as inhi-
bition of chondroprotective IL-4 could be predicted to
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have a reduced anabolic or even catabolic effect. How-
ever, the fact that reduced type I collagen baseline gene
expression followed treatment with IL-1Ra is an unex-
pected observation. These data therefore suggest
that treatment of human AF cells derived from both
nondegenerative and degenerative tissue with cytokine
inhibitors appears to have a different effect from that
previously observed in the presence of agonists.
Although treatment with either cytokine inhibitor
caused a decrease in type I collagen baseline gene
expression, exposure of the cells to 1.0-Hz CTS led to a
further decrease in gene expression, suggesting that
while IL-1 may be involved in basal collagen expression,
neither IL-1 nor IL-4 is necessary for this mechano-
transduction response. This lack of cytokine-dependent
mechanotransduction was also observed in the regula-
tion of aggrecan, where treatment of degenerative AF
cells with either cytokine inhibitor IL-1Ra or IL-4RAb
had no effect on baseline or 1.0-Hz CTS-induced down-
regulation of aggrecan gene expression.
Anabolic and catabolic gene expression is known to
occur through the involvement of different transcription
factors (for example, SRY (sex-determining region Y)-
box 9, or SOX9, and nuclear factor -light chain enhan-
cer of activated B cells (NFB) for matrix protein and
matrix-degrading enzyme gene regulation, respectively),
with specific transcription factors regulated via specific
signalling pathways (for example, IL-1-dependent NFB
regulation). Thus, differences in the regulation of matrix
protein and matrix-degrading enzyme gene expression
between AF cells derived from degenerative and nonde-
generative tissue, respectively, could be due to differ-
ences in cytokine-dependent transcription factor
activation brought about by the differential cytokine
involvement observed with 1.0-Hz CTS between nonde-
generative and degenerative AF cells.
This lack of involvement of IL-1 and IL-4 in the
mechanoresponse of degenerative cells indicates that an
altered mechanotransduction pathway may be in opera-
tion. Although cells from osteoarthritic cartilage have
also been shown to signal through an altered mechano-
transduction pathway in response to CTS [40], the
alteration in signalling occurred through the involve-
ment of an additional cytokine, namely IL-1b, and not
through the loss of cytokine signalling shown to be
necessary for mechanotransduction to occur in the
absence of disease as reported here. These changes in
signalling pathways indicate further differences in
mechanobiology between these cartilaginous cell types.
Interestingly, NP cells derived from degenerative tissue
have also been shown to utilise an altered mechanotrans-
duction pathway following stimulation with HP. Le
Maitre et al. [29] reported that the HP-induced
decrease in aggrecan gene expression occurred via an
RGD-recognising integrin pathway in NP cells derived
from nondegenerative, but not degenerative, tissue, sug-
gesting that disc cell mechanotransduction becomes
altered with degeneration, which is in agreement with the
results of this study.
Conclusions
In conclusion, this study has investigated the involve-
ment of the cytokines IL-1 and IL-4 in the mechano-
transduction pathways of human AF cells derived from
nondegenerative and degenerative tissue following
exposure to a stimulus previously shown to alter
matrix-regulating gene expression. We identified that
the altered mechanoresponse observed in AF cells
derived from degenerative tissue exposed to a CTS of
10% strain and 1.0-Hz frequency [18] may be the result
of an altered mechanotransduction pathway. Studying
the effect of CTS on human AF cells in vitro simplifies
the complexity of in vivo loading, enabling uncharac-
terised intrinsic factors to be removed from the system.
Although this nonphysiological loading environment
has limitations in terms of relevance to the in vivo
situation, removal of these uncharacterised biomecha-
nical and biochemical factors enables the effect of cell
deformation (and inevitably fluid flow) to be consid-
ered in isolation, allowing a more specific mechano-
transduction pathway to be investigated. Mechanical
forces are now well-recognised as important regulatory
factors in IVD cell biology, and differences in the
responses of cells from diseased discs are being
reported. To date, the mechanisms involved in enabling
IVD cells to respond to mechanical stimuli (and the
mechanisms preventing a “normal” response by cells of
diseased discs) remain largely unknown, demonstrating
a requirement for the continued elucidation of IVD
cell mechanotransduction, with the potential for the
discovery of novel therapeutic targets which could lead
to the prevention and/or treatment of DDD.
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